Other studies have also proved the meaningful therapeutic efficacy of osimertinib 160 mg, especially in brain and leptomeningeal metastases [10, 25, 26], whereas there was much less data on high‐dose aumolertinib for EGFR‐mutant NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.